ellaruth's  Instablog

Send Message
Employed in healthcare for 35 years. Interested in novel and destructively innovative healthcare technologies.
  • Monsanto's Beef To Dairy Begs For Brilacidin: Lifeway Definsin Mimetic Kefir? 6 comments
    Aug 10, 2014 10:53 PM | about stocks: CTIX, DOW, MON, ZTS, PFE, LWAY, MCD

    Beef and Dairy

    Beef and Dairy, soft serve and sandwich often go together. Ice cream, America's favorite past time. Throw in the over 300 billion hamburgers that MC Donald's (NYSE:MCD) has served, not counting milk, milkshakes and soft serve cones. The cheeseburger has cow in the bread, cheese and the beef in between. Specialized Nathan's famous hot dogs and Lifeway Food Co (NASDAQ:LWAY), Kefir. Imagine a definsin mimetic over the counter drink, spiked with a tiny bit of Kevetrin. After the 2b Brilacidin data comes in, Mr. Ehrlich and Ms. Smolyansky, should meet in Skokie and have an explorative chat.

    A cattle rancher, dairy farmer or urban factory worker can all see how important the cow is to America, and the worlds food supply. However, it is the first two of the prior mentioned that uniquely understand the vulnerabilities of the creatures that we know as cattle.

    A cattle rancher needs 40 acres of pasture land for each cow to graze in. If you have ever driven rural routes in cattle country, or road the Amtrak train east to west, you have past by some of the largest cattle ranches and fed lots in the world. Cattle of course need so much grazing pasture, so that there frequent excrement does not cover their green food supply. Cows walk through one another's shinsky, like canines, and felines walk through small puddles of dirty ground water. Have you ever smelled a cow pasture breeze? A feed lot is five times worse than a pasture. They are practically methane gas plants. However, I think its moron foolish to speak of a carbon tax applied to them.

    These big heavy four legged beasts, often have problems with nicks, cuts and open wounds about their legs and feet. They are similar to people like diabetics with foot ulcer's. However, the insult to the injury, is the cattle walking with open wounds through the potent bacteriological excrement, while continually grazing in hard bristly straw like grass.

    Cattle Foot Infections

    Cattle are expensive animals, there prices with regards to size, age and health can range from $2,000 to $5,000 per head. Each cow is an investment, LIVE STOCK! However, it is very easy to understand how bacteriological infections of the foot, are common place in cattle. One such is called "foot rot". The weight of the animal, it's physical movement in riveted terrain, all combine to make the antibiotic market for cattle very lucrative.

    The Mezzanine Livestock Antibiotic Malaise

    As cattle provide such a major contribution to the daily food supply. The better the antibiotic works in human's and the less likely it is to create antibacterial resistance in humans, the better it is to use the antibiotic in cattle. Our FDA currently has a block on this obvious truth being actionable. Problems resulting from antibiotics not approved for use in humans can result in beef or diary products showing amounts of unacceptable antibiotics. This is considered by some corporate intelligentsia to be debatable. Monsanto (NYSE:MON) is a poster board company in this debate. There are antibiotics that are not approved for human use, but are approved for livestock. Yes this mezzanine market allegedly regulated by the FDA is at ethical minimum, a nightmare conundrum. The self evident is that substantial quantities of these unapproved antibiotics accumulate in the food supply and therefore humans. It is often arguable as to the exact impact, but there are intelligent people like Senator Sherrod Brown, who accuse giant multi-national companies, in concert with regulators of not having the publics interest at heart. In order to offer the best alternative Senator Brown, needs to know about Brilacidin.

    Brilacidin's Potential 10 Billion Plus

    It appears as though Zoetis (NYSE:ZTS) has a number of products which it spun away with from Pfizer,(NYSE:PFE) that apply to both beef and dairy cattle. If Brilacidin completes FDA 2b with strong end point data. It is obvious to me that it will loom as a potentially a doubly superior antibiotic to anything in the livestock market for both animal feet and mouth. The public is yet to learn, and politicians have yet to feel the impact of their knowledge of definsin-mimetics. Once it becomes breakfast table knowledge that there are antibiotics that avoid creating antibacterial resistance, and that they are (?) FDA approved for humans. Then it would be reasonable and logical to double prefer highly potent defensin-mimetic antibiotics in our beef and dairy supply. If you follow my hyperlinks you can see that this has application into the realm of Agricultural, and also Industrial biotech. Brilacidin's annual global market potential is north of 10 billion dollars.

    Brilacidin Zoetis & The Antibiotic Market

    A post FDA 2b licensing for Brilacidin for the livestock market focusing on cattle, should be no less than $50 million dollars, which I estimate is about 7% of Zoetis annual revenue from livestock antibiotics. I am not able to divulge the method by which I extracted Zoetis livestock antibiotic income, it is a back door method, please do better if you can. I think my figures are conservative. I believe that Brilacidin, will be formulated to therapeutically equal or surpass any drug currently used to combat animal foot rot, however there will be scant chance of antimicrobacterial resistance which is of premiere importance for the global food supply. As the global market for antibiotics by 2016, is estimated to be 44 billion dollars. I believe that Brilacidin's defensin-mimetic antibacterial technology can comfortably claim 10 to 20% of that for self evident reasons.

    Brilacidin Veterinarian License Worth $50 Million

    The post 2b licensing of Brilacidin to veterinarian and more specifically livestock markets could generate enough cash, plus percentage of future sales, that it alone constitutes a non dilutive financing option for Cellceutix through to the end of 2016 (OTCMKTS:CTIX).

    Monsanto Can Come To The Light

    If Monsanto has a ray of light left in their darkened participation in the mezzanine antibiotic biotic market, it's management would find a posthaste evaluation of Brilacidin to be something that would be in both their moral and financial best interest. To Monsanto, every socially conscious company has a past and every socially callous company has a future. Dow Chemical (NYSE:DOW) might do well to hear the same.

    Cellceutix is a socially conscious investment. I now own over 10,000 shares. I am willing to loose my total investment. Would rather die on the titanic, than drown on a canoe.

    Ella Ruth... You Can Call Me Crazy Also!

Back To ellaruth's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (6)
Track new comments
  • ellaruth
    , contributor
    Comments (1094) | Send Message
    Author’s reply » Please see today's announcement from the CEO, Leo. I have chopped the disclaimer, which warns, that you can loose any part of or all of your investment, buying shares in trial stage drug companies.


    Cellceutix Prepares for Phase 2 Clinical Trial of Brilacidin-OM for Oral Mucositis


    Cellceutix Corporation (OTCQB: CTIX) (the "Company"), a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology, and antibiotic applications, is pleased to announce that the Company has just received the final toxicology report for Brilacidin-OM. Cellceutix is developing Brilacidin-OM as a new treatment for oral mucositis, a common and often debilitating inflammation and ulceration that occurs in the mouth as a side effect of certain cancer treatments, including chemotherapy and radiation therapy.


    Cellceutix is reviewing the report, which will be added to finalize the already prepared Investigational New Drug (NYSE:IND) application for submission to the U.S. Food and Drug Administration seeking approval to commence a Phase 2 clinical trial of Brilacidin-OM as soon as possible.


    “The past week was full of great news for us; that enrollment for the Phase 2b trial of Brilacidin for Acute Bacterial Skin and Skin Structure Infections will be completed this month, the statistical data on our anti-psoriasis drug Prurisol showed that it attained it's primary endpoint in a Phase 1 trial, and now the data to complete the IND for Brilacidin-OM. We look forward to the IND submission in a bid to fill an area of great unmet medical need to the nearly half a million patients that suffer the painful effects of oral mucositis every year,” commented Leo Ehrlich, Chief Executive Officer of Cellceutix.


    Mr. Ehrlich added, “On a broader perspective, the question has been posed to me about what last week’s FDA approval of The Medicines Company’s oritavancin, a one-time treatment for ABSSSI, means to Brilacidin. First, we congratulate The Medicines Company on their approval. Candidly, we do not view oritavancin as a potential competitor to our Brilacidin because of several key differentiators, namely pharmacokinetic profiles and subsequent implications. Ortavancin is a lipoglycopeptide, the same class of drug as Durata Pharmaceutical’s Dalvance®


    (Dalbavancin), and both drugs have a very long half-life of approximately one to two weeks. This means that the drug remains in a patient’s system for a considerable period following dosing, which has the potential for contraindication with other medicines and questions concerning metabolism and drug resistance. Brilacidin, a new class of drug, has a half-life of only 13 to 16 hours, a time frame that we believe is ideal for a one-time treatment, while greatly decreasing the chance of resistance developing. Further, Brilacidin in its clinical trials is being tested compared to daptomycin, a superior drug to vancomycin, which was the comparator arm in the pivotal trials of ortavancin and Dalvance. Overall, in addition to the direct comparison with ABSSSI, we look at our asset as offering much more potential as an antibiotic, especially with room temperature formulations paving the way for possibly treating a wide range of other indications, such as diabetic foot ulcer infections, ophthalmic infections and otitis media. ABSSSI alone is more than a billion-dollar market and growing, and there is room for everyone with the best drug taking the lion’s share of dollar sales. So while we applaud a new therapeutic option for patients, we are not concerned about the approval of ortavancin.”


    11 Aug 2014, 07:53 AM Reply Like
  • 291
    , contributor
    Comments (35) | Send Message
    Ella, I like your thoughts here as it would put dilution to rest and fatten the bank account while waiting on k an p and b to play out in the upcoming trials. Is the regulatory pathways for animal use different than humans?
    11 Aug 2014, 03:34 PM Reply Like
  • ellaruth
    , contributor
    Comments (1094) | Send Message
    Author’s reply » 291
    The regulatory pathway is different, but Brilacidin has a double advantage. 1st I believe that Brilacidin, is going to be approved by the FDA for human utilization. Well you say so are many other antibiotics. Then we see that an FDA human approved definsin mimetic dovetails perfectly as a scientific answer to both the regulators, consumers, and controllers of the beef to dairy market. Other human approved drugs pale in safety comparison to those drugs of definsin mimetic technology. Is Brilacidin powerful, perhaps even more so.


    The regulatory pathway is different, it would appear as though after stage 3 or 4 human trial that Brilacidin would move briskly through Animal trials. Indeed the FDA data could be negotiated.


    There is one things to watch, the rogue market for unapproved antibiotics has made some companies a fortune. An immoral lazy person will often become very angry when their rogue markets are exposed, and threatened with extinction. A major group might want to buy the CTIX technology just to put it on the shelf for 5 years or slow it down.


    Ella Ruth
    11 Aug 2014, 09:28 PM Reply Like
  • 291
    , contributor
    Comments (35) | Send Message
    Thanks for the reply and keep up the good work.
    12 Aug 2014, 09:44 AM Reply Like
  • Dody23
    , contributor
    Comments (59) | Send Message
    Huge, huge Fan of yours.
    I just cannot stand the names of Monsanto and Dow. Those two companies could possibly destroy our ecosystem. So when you says "Ray of Light" I'm not sure they every had or will have a ray of light. I so much hope I'm wrong.


    I know you are very forward thinking on CTIX as am I, but this will take years and will have to have some very good fortune to work out.
    We raised cattle and those soars eventually get on almost all the cattle and something HAS to be Changed about the way cattle are currently being treated with Gobs of Antibiotics as I have a family of Veterinarians. Yes, we are eating those antibiotics and they need something that will work very quickly and very effectively with short half life to deter resistance.
    I appreciate and do enjoy your articles.
    12 Aug 2014, 12:36 PM Reply Like
  • ellaruth
    , contributor
    Comments (1094) | Send Message
    Author’s reply » Dody


    First you've got experience and family connections that I do not have. So I humbly bow to the weight of both, and hope that you share more soon.


    However a bill like Senator Browns stuck between Democrats and Republicans, who do not have the publics best interest at heart.Might become a patent force when the eventual superbug pandemic emerges, in similar fashion as the Ebola virus recently has. If we have the major bacteriological pandemic predicted you could see legislation by scared politicians that would seem to answer some of your prayers.


    I do understand what you haveindicated about Monsanto and Dow, however they have a choice. They can continue to do what I liken as, corporate red light district compound pushing, or they can buy in to definsin mimetic Brilacidin technology.


    Yes, I think it better to plan for years, but as I see it there are catalysts looming that will accelerate this beyond the resistance of the red light district drug charlatans, who parade themselves as blue chip quality Fortune 500 companies.


    Both now and later Sherrod Brown, and others who chose to have a conscience now have an alternative to offer. Prior to Brilacidin, they only had regular approved antibiotic's and all of those fail the big all important anti- micro- bacteriological resistance testWith Brilacidins eventual FDA approval, Sherrod Brown's proposed evolution can be safely bet as having become a revolution.


    So Brilacidin started low, has gone slow, butwill climb higher and then catch fire.


    Let's enjoy the trip and expect acceleration. There are a number of smaller animal science companies that may make much better partner's that the big two. Indeed Leo, should only give them an entry point, if they pay good and agree to milestones on a time event trajectory. We should only trust a very strong agreement and upfront payment with a major like Monsanto, and or Dow.


    Once definsin mimetic technology is heralded on the pubic news shows, explained by Jim Cramer and talked up by analysts. Socially conscious investor will begin to raise the critical issue of why are we still using UNAPPROVED ANTIBIOTICS IN OUR FOOD SUPPLY. When those canaries begin to sing in the coal mines and the barber shops of America, watch out CTIX has an entire group of definsins for both animal, industrial and agricultural (lots of fungus) that an approved Brilacidin will shine the light on. A number of companies might be threatened with shareholder disinvestment if they continue this rogue practice. In turn an FDA approved Brilacidin may give CTIX an expanding PE.


    At such time you will hear someone say the Poly Medix asset portfolio might be worth north of 25 billion dollars in the spectrum between human, animal, agricultural and industrial biotech.


    Thanks for sharing


    12 Aug 2014, 11:40 PM Reply Like
Full index of posts »
Latest Followers


  • Budget for all operating expenses was 16.7 m, but they only spent $12.9 m. CTIX has come in under projected budget every year for 7 years!.
    Sep 14, 2016
  • I HUB's B Kahuna RSVP CTIX 10K Notice the company spent only $9 m for trials and drug development for the year? The projection was 12m.
    Sep 14, 2016
  • CTIX mgmt adv 5 drugs in clinical trials over 3 years on less than $25m. Imagine how far they can go w $50m plus a few 100m in milestones.
    Sep 14, 2016
More »

Latest Comments

Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.